Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Long-Term Deferred Tax (2019 - 2025)

Autolus Therapeutics (AUTL) has disclosed Long-Term Deferred Tax for 6 consecutive years, with $2.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Deferred Tax fell 29.51% year-over-year to $2.4 million, compared with a TTM value of $2.4 million through Sep 2025, down 29.51%, and an annual FY2024 reading of $3.2 million, up 5.75% over the prior year.
  • Long-Term Deferred Tax was $2.4 million for Q3 2025 at Autolus Therapeutics, down from $2.4 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $3.4 million in Q3 2024 and bottomed at $2.0 million in Q1 2022.
  • Average Long-Term Deferred Tax over 4 years is $2.7 million, with a median of $2.7 million recorded in 2023.
  • The sharpest move saw Long-Term Deferred Tax skyrocketed 47.54% in 2023, then dropped 29.51% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $2.1 million in 2022, then soared by 47.54% to $3.1 million in 2023, then grew by 5.75% to $3.2 million in 2024, then fell by 26.24% to $2.4 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for AUTL at $2.4 million in Q3 2025, $2.4 million in Q2 2025, and $2.8 million in Q1 2025.